Furthermore, the combination of RA with HDAC inhibitors in patients with RA-resistant APL (such as those bearing the PLZF–RAR chimera) has produced encouraging clinical responses, although some blasts remain resistant to differentiation [88,90]. This evidence concerns the gene HDAC9 and acute promyelocytic leukemia.